This inventor holds 3 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Sony Group Corporation, Other. Active years: 2022-2026.
Company Filing History:
2 out of 4,209 
1 out of 834,411 Years Active: 2022-2026
Title: Lantao Li: Innovator in Pharmaceutical Compounds
Introduction
Lantao Li is a prominent inventor based in Beijing, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific biological pathways. His work focuses on creating innovative solutions for treating autoimmune diseases and cancers.
Latest Patents
Lantao Li holds a patent for a novel compound known as a 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound. This compound acts as a JAK inhibitor, showcasing high JAK inhibitory activity. The patent also covers its isomers, solvates, hydrates, pharmaceutically-acceptable salts, and prodrugs. The pharmaceutical composition containing this compound is intended for use in preparing medicaments for treating autoimmune diseases or cancers.
Career Highlights
Throughout his career, Lantao Li has worked with various organizations, including Beijing Scitech-Mq Pharmaceuticals Limited. His expertise in pharmaceutical development has positioned him as a key figure in the industry, contributing to advancements in medical treatments.
Collaborations
Lantao Li has collaborated with notable professionals in his field, including Qiang Zhang and Yansheng Liu. These partnerships have facilitated the exchange of ideas and fostered innovation in pharmaceutical research.
Conclusion
Lantao Li's contributions to the field of pharmaceuticals, particularly through his patent for a JAK inhibitor compound, highlight his role as an innovator. His work continues to pave the way for new treatments in the medical field.